The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Impact of antibiotic resistance on clinical outcomes and the cost of care
Abstract
Antibiotic-resistant organisms are common in intensive care unit infection and can be either Gram-positive or Gram-negative. A number of studies have evaluated whether these organisms can lead to excess morbidity, mortality, or cost. In general, the studies are confounded by a number of methodologic issues, including the selection of an appropriate control population. Cases and controls must be appropriately matched for the presence of infection, the presence of infection with similar organisms (but ones that are either antibiotic-sensitive or -resistant), and severity of illness. In addition, studies must account for the therapies given to patients who are infected with resistant organisms because resistance is an important risk factor for inadequate empirical therapy, and such therapy is itself a potent determinant of a number of adverse outcomes, including mortality. To date, the data with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus are inconsistent with regard to the effect on mortality rates, although infection with both organisms can lead to excess length of stay and increased cost of care. When studies have been adequately controlled and powered, infection with vancomycin-resistant enterococcus has had more of an effect on the mortality rate than infection with antibiotic-sensitive enterococci. Infection with resistant Gram-negatives also has adverse impact on outcome, with excess mortality being seen in patient groups infected with Acinetobacter and Pseudomonas aeruginosa. If we are to minimize the effect of resistance on medical outcomes and cost, it will be necessary to have a current knowledge of each intensive care unit's pathogens and susceptibility patterns, so that empirical therapy will have a good likelihood of being effective. In addition, new therapeutic agents may improve on the efficacy of older agents and could reduce cost if they allow for some patients to leave the hospital and to finish therapy with an oral formulation of a highly bioavailable agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
Cited by
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Efflux-mediated multiresistance in Gram-negative bacteria
Poole, K. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00763.x · Cited by 613
Safdar, N., Handelsman, J., & Maki, D. G. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01108-9 · Cited by 417
Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization
Sunenshine, R. H., Wright, M.-O., Maragakis, L. L., Harris, A. D., Song, X., Hebden, J., Cosgrove, S. E., Anderson, A., Carnell, J., Jernigan, D. B., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1301.060716 · Cited by 411
Acinetobacter Outbreaks, 1977–2000
Villegas, M. V., & Hartstein, A. I. (2003) · Infection Control & Hospital Epidemiology · doi:10.1086/502205 · Cited by 402
Metadata
- Authors
- Niederman, M. S.
- Venue
- Critical Care Medicine
- Published
- 2001-04
- Volume
- 29
- Issue
- Supplement
- Pages
- N114-N120
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2008505896
- Cited by
- 167
- References
- 1
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of antibiotic resistance on clinical outcomes and the cost of care. https://app.cochat.ai/papers/10.1097/00003246-200104001-00011
- The paper
- Niederman, M. S. (2001). Impact of antibiotic resistance on clinical outcomes and the cost of care. Critical Care Medicine. https://doi.org/10.1097/00003246-200104001-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.